Pain Therapeutics, Inc. Forecasted to Post FY2021 Earnings of ($0.35) Per Share (PTIE)

Pain Therapeutics, Inc. (NASDAQ:PTIE) – Research analysts at Gabelli issued their FY2021 earnings per share estimates for Pain Therapeutics in a research note issued on Thursday, according to Zacks Investment Research. Gabelli analyst K. Kedra anticipates that the biopharmaceutical company will earn ($0.35) per share for the year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://transcriptdaily.com/2017/04/22/pain-therapeutics-inc-forecasted-to-post-fy2021-earnings-of-0-35-per-share-ptie.html.

Pain Therapeutics (NASDAQ:PTIE) traded down 1.3384% during mid-day trading on Friday, reaching $0.7814. The company’s stock had a trading volume of 249,263 shares. Pain Therapeutics has a 12-month low of $0.51 and a 12-month high of $3.00. The company’s market cap is $36.05 million. The firm’s 50 day moving average is $0.79 and its 200-day moving average is $0.67.

A number of large investors have recently bought and sold shares of PTIE. Gabelli Funds LLC boosted its stake in Pain Therapeutics by 9.4% in the fourth quarter. Gabelli Funds LLC now owns 175,000 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 15,000 shares during the period. BVF Inc. IL raised its position in Pain Therapeutics by 6.0% in the third quarter. BVF Inc. IL now owns 2,278,552 shares of the biopharmaceutical company’s stock valued at $2,278,000 after buying an additional 128,639 shares in the last quarter. Spark Investment Management LLC purchased a new position in Pain Therapeutics during the third quarter valued at approximately $119,000. Finally, Acadian Asset Management LLC raised its position in Pain Therapeutics by 26.3% in the third quarter. Acadian Asset Management LLC now owns 443,430 shares of the biopharmaceutical company’s stock valued at $444,000 after buying an additional 92,358 shares in the last quarter. 44.34% of the stock is owned by institutional investors.

Pain Therapeutics Company Profile

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

5 Day Chart for NASDAQ:PTIE

Get a free copy of the Zacks research report on Pain Therapeutics (PTIE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com